'Trained immunity' from *Mycobacterium* spp. (environmental or BCG) exposure predicts protection from Coronavirus disease 2019 (COVID-19)

Samer Singh, Ph.D. [1,#]; Rakesh K. Singh, Ph.D.[2]

[1]Centre of Experimental Medicine & Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi - 221005, India

[2]Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi – 221005, India

[#]**Address for correspondence:** samer.singh10@bhu.ac.in

ABSTRACT:

Endeavors to identify protective variables that could be potentially responsible for reduced COVID-19 impact on certain populations have remained a priority. Multiple attempts have been made to attribute the reduced COVID-19 impact on populations to their bacillus Calmette–Guérin (BCG) vaccination coverage ignoring the fact that the effect of childhood BCG vaccination wanes within the first 5 years of life while most of the COVID-19 cases as well as deaths have been observed in adults especially the aged with comorbidities. Since the supposed desired protection being investigated could come from heterologous 'trained immunity' conferred by exposure to *Mycobacterium* spp. (*i.e.,* environmental and BCG), it is argued that the estimates of the prevalence of 'trained immunity' of populations currently available as latent tuberculosis infection (LTBI) of populations would be a better variable to evaluate such assertions. Indeed, when we analyze the European populations (twenty-four) as well as erstwhile East and West Germany populations completely disregarding their BCG vaccination coverage, the populations with higher trained immunity prevalence consistently display reduced COVID-19 impact as compared to their lower trained immunity prevalence neighbors. The incidences, mortality, and interim case fatality rates (i-CFR) of COVID-19 are found negatively correlated with the trained immunity of populations that have comparable underlying confounders not the BCG coverage *per se*. It is submitted that to decisively arrive at dependable conclusions about the potential protective benefit that can be gained from BCG vaccination in COVID-19, the ongoing/planned randomized controlled trials should consciously consider including measures of trained immunity as - a) all individuals immunized do not respond equally, b) small study groups of higher background trained immunity could fail to indicate any protective effect.

Key Words: COVID-19, Trained Immunity, bacillus Calmette–Guérin, BCG, Tuberculin Sensitivity Test (TST), pandemic, SARS-CoV-2

INTRODUCTION

There have been efforts to understand and explain the differential impact of COVID-19 on populations in pursuance of identifying protective variables that could predict the impact or be applied for intervention. Recent studies in PNAS and Science Advances (1,2) had endeavored to explain/model the differential effect on populations based on 'trained immunity' correlates of countries' as per bacillus Calmette–Guérin (BCG) vaccination rates after meticulous correction/fitting of the data for supposed major confounders like age, population density, development status, BCG coverage/implementation using the infections and mortality data from an early stage of pandemic (till April 22). More recently, other communications in PNAS (3,4) have failed to find support for the association previously observed between BCG and the impact of COVID-19 on populations when using updated data set.

The extrapolation of associative observations made previously (1,2) linking BCG vaccination coverage to reduced COVID-19 impact on populations was expected to disappear (3-5) as the 'trained immunity' conferred by childhood BCG vaccination usually wanes in <5 years (5-7). Hence, the premise of protective 'trained immunity' from BCG vaccination given in childhood or to children in a population is not supposed to decrease the severity of infection or supposedly provide any protection in currently aged as the BCG conferred 'trained immunity' correlates would have waned away long ago (5-7). The use of early-stage pandemic data (1,2) when the populations were not evenly exposed along with displayed associations' inherent disconnect with the mechanism proposed behind the observed protective correlation make such assertions untenable.

We reason, the dependability on the correlative associations as well as conclusions presented in refs. (1-4) would tremendously improve on considerations: a) direct measure of prevailing supposed protective 'trained immunity' correlate (TIC) as a result of populations exposure to *Mycobacterium* spp. or BCG vaccination (5,6,7), *i.e.,* Tuberculin positivity [TIC of BCG given at birth wanes within <5 years (6), so chances of heterologous protection (8) of elderly from childhood vaccination are remote]; b) analysis of countries at a similar stage of the pandemic; c) underlying confounders including potential contributory variables (e.g., Vitamin D, Zinc) (9,10); d) the correlations observed, at any time, to be the total sum of the effects from protective variable and preventive/curative measures in place (e.g., social distancing norms and adherence, medical infrastructure/support).

The European populations with quite dissimilar BCG coverage (including no vaccination) that have experienced differential COVID-19 impact [11] offer an excellent opportunity to evaluate the alternative hypothesis that the 'trained immunity from *Mycobacterium* spp. exposure (BCG or environmental NOT

the childhood vaccination coverage *per se*) could be protective in COVID-19. It would be theoretically better equipped to predict the flattened curve if any such association exists, that may have cause and effect relationship. The analysis of TIC and COVID-19 data from 24 socially similar European countries support a potential protective role for the prevalent TIC of populations on COVID-19 infections and mortality.

MATERIAL AND METHODS:

The COVID-19 incidence and mortality data for the European countries (Supp. Table 1) was obtained from Worldometer (11; https://www.worldometers.info/coronavirus/ [Accessed on 27 August]) and that of East and West Germany states from https://www.citypopulation.de/en/germany/covid/ [Accessed on 10 October 2020] and previously published estimates (7). The latent tuberculosis infection (LTBI) (12) prevalence estimates (i.e., 'trained immunity' correlate) were from reference (13). All statistical estimations and correlation analysis of the COVID-19 incidence and mortality with TIC or LTBI prevalence of populations (Average, Standard deviation (STDEV), Standard Error (Std. Err.), F-value, Correlation/ Pearson coefficient (r/R), regression, *etc*) were performed using Microsoft Excel 2019. The *p*-values <0.05 were considered significant unless explicitly stated otherwise. The methodology employed has been essentially the same as described previously (5,7,9,10).

RESULTS & DISCUSSION:

Analysis of the updated COVID-19 data (till 28 August, Sup. Table 1, ref. 11) from 24 European countries with similar confounders (ref.1 and additional), stage of the pandemic, without any exclusions (applied in ref. 1. and 3.) consistently displayed protective/negative correlation with the direct measure of desired heterologous TIC of populations [i.e., tuberculin positivity without active tuberculosis disease; referred by WHO as Latent tuberculosis infection (LTBI) for the management purposes (12-13)]. Higher LTBI populations consistently displayed lower COVD-19 incidence/mortality per million and interim case fatality rates (i-CFR) (Fig. 1). The correlations observed shown here are supposed to decline further before the disappearance of COVID-19 due to progressive loss of synchronicity of infections/ pandemic-phases (Sup. Fig. 2), lower prevalence of the protective variable (6.06 - 15.95%) (13), the differential response of the study population, etc. not necessarily the supposed absence of correlation (3).

Similarly, East and the West Germany States displayed significant negative covariation of cases, mortality, and i-CFR rates with estimated TIC of populations (22.5% and 9.2% LTBI, respectively) without requiring correction factors (10 April – 28 August; Fig. 2). Expectedly, the differential response gap seen for East and West Germany is showing signs of closing as expected for populations slowly reaching towards stable equilibrium with underlying confounders (Fig. 2C).

In conclusion, we believe the incidences, mortality, and i-CFR of COVID-19 would negatively correlate with the trained immunity of populations that have comparable underlying confounders, not the BCG coverage *per se*. To decisively arrive at dependable conclusions about the potential protective benefit of BCG in COVID-19, the ongoing/planned randomized controlled trials should consciously consider including measures of TIC [14,15] as - a) all individuals immunized do not respond equally, b) small study groups of higher background trained immunity could fail to indicate any protective effect. Currently under development COVID-19 vaccines still have a long way to go and be available in sufficient supply to cover the whole global population at the same time to confer the much-needed 'herd immunity' whereas BCG is readily available and may give us respite. Any potential protective effect displayed by BCG vaccination in the ongoing trials, especially in aged and persons with comorbidities who are currently accounting for more than 90% deaths, could help provide hope in the current scenario.

Funding: No specific source of funding was utilized for the current study. However, SS acknowledges the funding support to his laboratory from the Institute of Eminence (IoE) seed grant, Banaras Hindu University.
Competing Interest: The authors declare no competing interest.
Author contribution: SS designed the research, analyzed the data, and wrote the paper; RK contributed to analysis and drafting.

REFERENCES:

1. Escobara LE, Molina-Cruzb A, Barillas-Mury C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). PNAS 2020; 117: 17720-17726; www.pnas.org/cgi/doi/10.1073/pnas.2008410117
2. Berg MK, Yu Q, Salvador CE, Melani I, Kitayama S. Mandated Bacillus Calmette-Guérin (BCG) vaccination predicts flattened curves for the spread of COVID-19. Sci Adv. 6, eabc1463 (2020).

3. Arlehamna CSL, Settea A, Peters B. Lack of evidence for BCG vaccine protection from severe COVID-19. PNAS 2020; 117: 25203–25204; www.pnas.org/cgi/doi/10.1073/pnas.2016733117

4. Patella V, Delfino G, Bruzzese D, Giuliano A, Sanduzzi A. The bacillus Calmette–Guérin vaccination allows the innate immune system to provide protection from severe COVID-19 infection. PNAS 2020, 117 (41) 25205-25206; DOI: 10.1073/pnas.2015234117

5. Singh S. BCG Vaccines May Not Reduce Covid-19 Mortality Rates. medRxiv 2020.04.11.20062232. https://doi.org/10.1101/2020.04.11.20062232

6. Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med. 1999 Jan; 159(1):15-21

7. Singh S, Maurya RP, Singh RK (2020) "Trained immunity" from Mycobacterium spp. exposure or BCG vaccination and COVID-19 outcomes. PLoS Pathog 16(10): e1008969. https://doi.org/10.1371/journal.ppat.1008969

8. O'Neill LAJ, Netea MG. BCG-induced trained immunity: can it offer protection against COVID-19?. Nat Rev Immunol 2020; 20: 335–337. https://doi.org/10.1038/s41577-020-0337-y

9. Singh S, Kaur R, Singh RK. Revisiting the role of vitamin D levels in the prevention of COVID-19 infection and mortality in European countries post infections peak. Aging Clin Exp Res. 2020;32(8):1609-1612. doi:10.1007/s40520-020-01619-8

10. Singh S. Covariation of Zinc Deficiency with COVID19 Infections and Mortality in European Countries: Is Zinc Deficiency a Risk Factor for COVID-19? J Sci Res. 2020;64(2):153–157.

11. Worldometer. COVID-19 Coronavirus Pandemic. https://www.worldometers.info/coronavirus/ [Accessed on 27 August]

12. WHO. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. 2018. ISBN 978-92-4-155023-9. [Available at https://apps.who.int/iris/bitstream/handle/10665/260233/9789241550239eng.pdf;jsessionid=24D3F1097E3884502A9C1A1698348491?sequence=1]

13. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2017 (GBD 2017) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 2018. [Available from http://ghdx.healthdata.org/gbd-results-tool; search term combination "Prevalence - Latent Tuberculosis Infection - Sex: Both - Age: All Ages (Percent)"]

14. BCG vaccination and COVID-19 trials (19) listed at https://clinicaltrials.gov[https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=BCG&cntry=&state=&city=&dist=&Search=Search]

15. Hamiel U, Kozer E, Youngster I. SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults. JAMA. 2020; 323(22): 2340-2341. doi:10.1001/jama.2020.818

Fig. 1. The COVID-19 cases, deaths and CFR consistently remained lower in European populations with higher trained immunity (TI) correlate (>10% LTBI) post-peak-of infections than countries with the lower TI-correlate (<10% LTBI). The TI-correlate indicated a significant consistently negative association with COVID-19 infections [Pearson correlation r(24): -0.79 to -0.57, p-value<0.005] and mortality [r(24)= -0.63 to -0.45, p-value<0.05)] for the whole time period (12 March to 26 August 2020). See Sup. Fig 1 in conjunction with Sup. Fig. 2 for detailed correlation analysis and its variation with wave of infections across 24 countries. Refer to Sup. Table 1 for updated COVID-19 cases and deaths data for the 24 countries with supposedly similar confounders and at similar stage of pandemic included in the study. (A) The i-CFR [(deaths/cases)*100] for Low LTBI countries had remained higher than that of high LTBI countries post infections peak. (B) Low LTBI countries have had relatively higher infections/million population (1.63 fold on 26 August) and consistently higher i-CFR (~30% on 26 August).

Fig 2. East Germany states with higher trained immunity correlate (%LTBI) as compared to West Germany states (22.5% vs 9.2%) consistently reported lower COVID-19 cases (A), deaths (B) and i-CFR (C) during study period (10 April to 28 August). Refer to Sup. Table 2 for COVID-19 cases and deaths and Sup. Table 3. for i-CFR estimates. E. Germany consistently had 20-30% lower CFR as compared to W. Germany states. The inclusion of Berlin in East Germany region, and that of Hamburg and Bremen in West Germany region decreased the closing trend of the i-CFR with passage of time (compare covariation of Red and Green trend lines with Orange and Light green in (C) possibly indicative of more LTBI positives in Berlin than in Hamburg and Bremen. **In future**, as the pandemic progresses the gap between E. and W. Germany states is expected to close, partially resulting from decrease in the vulnerable population and the concomitant increase in populations overall 'trained immunity' as a result of infections.

Sup. Fig.1. The COVID-19 cases (A) and Deaths (B) in European countries with similar confounders and stage of pandemic consistently remained negatively and significantly correlated with Trained immunity prevalence (est. %LTBI) starting from March 12 to August 26. See Supp. Fig 2 for correlation analysis for the period starting from 12 March to 26 August 2020 covering the duration upto April 22 of ref.1 and August 1 reference point of ref. 2.

CORRELATION ANALYSIS: COVID-19 CASES per MILLION (Log10) vs % LTBI Prevalence

Data-Date	12 Mar	26 Mar	12 Apr	26 Apr	12 May	26 May	12 Jun	26 Jun	12 Jul	26 Jul	12 Aug	26 Aug
Corr. $r(24)$ /R-value	-0.7572	-0.8066	-0.8207	-0.8062	-0.7851	-0.7642	-0.7311	-0.6891	-0.6435	-0.6107	-0.5856	-0.5711
R^2	0.5733	0.6507	0.6735	0.6499	0.6163	0.5840	0.5345	0.4749	0.4141	0.3729	0.3429	0.3261
Adj. R^2	0.5540	0.6348	0.6587	0.6340	0.5989	0.5650	0.5133	0.4511	0.3875	0.3444	0.3130	0.2955
Std. Err.	0.9931	0.4309	0.3112	0.2789	0.2703	0.2700	0.2767	0.2841	0.2860	0.2855	0.2831	0.2760
F-value	29.5642	40.9771	45.3808	40.8368	35.3386	30.8784	25.2568	19.8988	15.5494	13.0824	11.4790	10.6469
p-value	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0002	0.0007	0.0015	0.0026	0.0036

CORRELATION ANALYSIS: COVID-19 DEATHS per MILLION (Log10) vs % LTBI Prevalence

Data-Date	12 Mar	26 Mar	12 Apr	26 Apr	12 May	26 May	12 Jun	26 Jun	12 Jul	26 Jul	12 Aug	26 Aug
Corr. $r(24)$ /R-value	-0.4127	-0.5523	-0.6566	-0.6700	-0.6343	-0.6013	-0.5713	-0.5484	-0.5237	-0.5041	-0.4761	-0.4554
R^2	0.1703	0.3050	0.4311	0.4489	0.4024	0.3615	0.3264	0.3007	0.2743	0.2541	0.2266	0.2074
Adj. R^2	0.1326	0.2734	0.4052	0.4238	0.3752	0.3325	0.2958	0.2689	0.2413	0.2202	0.1915	0.1714
Std. Err.	1.7606	1.0551	0.6009	0.5056	0.4993	0.5006	0.5044	0.5051	0.5071	0.5078	0.5056	0.5034
F-value	4.5153	9.6559	16.6689	17.9169	14.8131	12.4572	10.6610	9.4613	8.3139	7.4942	6.4473	5.7564
p-value	0.0451	0.0051	0.0005	0.0003	0.0009	0.0019	0.0035	0.0055	0.0086	0.0120	0.0187	0.0253

Sup. Fig 2. The correlation between underlying prevailing trained immunity correlate (%LTBI) of European populations with COVID-19 cases per million (A) and deaths per million (B) and its dependence on phase of pandemic. The observed correlation (see bottom correlation analysis table) consistently remained negative for the period. The notification rates for countries with >10% LTBI is indicated by broken lines. Correlation remained high with the synchronicity of 1st peak of infections (see corresponding notification rates graph above for the data date indicated in the table below) and been on decline since then partially resulting from the loss of synchroncity, populations response, acquired immunity and understandably and importantly the changing reporting and management practices. ***Refer to Sup. Fig. 3 from European CDC that more accurately reflects the waves of infections/deaths from starting not explicitly observable in the figure one presented here due to coarse methodology employed***. The response of populations had been more stringent and uniform for 1st wave of infections. ***Note:*** **The highlighted *12-May* and *26-May* values _could_ reflect the assumed total sum of actual maximum achievable correlation for potential 'trained immunity' along with current confounders and the stringent measures put in place by the countries to reduce the spread of COVID-19 – _NOT_ necessarily due to only the prevailing trained immunity of the populations as a result of BCG coverage or implementation alone as assumed (ref.1 and 2.).** **Even if there is a cause and effect relationship**, **the expected protective covariation** (correlation) would expectedly further go down for reasons mentioned above. It may soon reach **0.2-0.4 for the study populations** primarily _due to increasingly heterogenous (loosened) response combined with actual low trained immunity prevalence)._.

EU/EEA and the UK: 14-day COVID-19 case and death notification rates

Regional totals as of 11 Oct 2020: 4 065 835 cases (earliest 25 Jan, latest 11 Oct 2020), 195 235 deaths (15 Feb, 11 Oct 2020)

— 14-day case notification rate per 100 000 population   — 14-day death notification rate per 1 000 000 population

ECDC. Figure produced 15 October 2020.
Source: Epidemic intelligence, national daily data

Sup. Table 1. COVID-19 data [Cases per million (CpM) and deaths per million DpM]of European countries

Countries	CpM 12 Mar	DpM 12 Mar	CpM 26 Mar	DpM 26 Mar	CpM 12 Apr	DpM 12 Apr	CpM 26 Apr	DpM 26 Apr	CpM 12 May	DpM 12 May	CpM 26 May	DpM 26 May	CpM 12 Jun	DpM 12 Jun	CpM 26 Jun	DpM 26 Jun	CpM 12 Jul	DpM 12 Jul	CpM 26 Jul	DpM 26 Jul	CpM 12 Aug	DpM 12 Aug	CpM 26 Aug	DpM 26 Aug	Population	LTBI 2017 (%)
Spain	665.43	1.84	3118.24	93.35	4667.48	368.05	5243.71	495.96	5493.08	574.36	5622.58	595.47	5738.28	604.71	5819.68	606.06	6019.13	607.49	6584.73	608.11	8063.46	611.21	9581.54	619.60	46757733	6.06
Iceland	342.51	0.00	2347.79	5.85	4979.54	23.42	5245.93	29.27	5272.28	29.27	5281.06	29.27	5289.84	29.27	5327.90	29.27	5365.96	29.27	5406.94	29.27	5772.87	29.27	6094.88	29.27	341598	7.67
Ireland	14.15	0.20	367.73	3.84	1950.46	67.52	3892.64	218.94	4697.25	300.01	4999.08	325.68	5103.19	343.88	5136.34	348.93	5181.02	352.98	5232.17	356.21	5425.64	358.64	5733.94	359.24	4946514	8.14
Finland	19.67	0.00	172.86	0.90	536.62	10.10	825.68	34.28	1083.16	49.62	1195.93	56.30	1276.23	58.64	1297.52	59.18	1315.92	59.18	1333.97	59.36	1378.89	60.09	1443.85	60.45	5542120	8.28
Netherlands	35.82	0.29	433.52	25.32	1492.73	159.68	2207.86	261.07	2507.67	321.45	2659.00	341.64	2827.19	353.13	2917.27	356.05	2976.60	357.91	3088.85	358.20	3536.95	359.43	3973.74	362.58	17141028	8.29
Switzerland	100.18	0.81	1363.11	22.16	2933.15	127.64	3353.93	185.81	3506.16	215.47	3550.13	221.01	3633.80	223.66	3795.03	226.43	3971.49	227.13	4289.68	228.17	4690.84	229.78	5235.42	231.17	8664751	8.42
Norway	147.38	0.18	621.22	2.58	1202.10	23.58	1386.69	37.03	1502.76	42.00	1544.40	43.29	1588.06	44.58	1627.11	45.87	1654.56	46.43	1679.62	46.98	1802.32	47.16	1935.15	48.64	5428015	8.46
Belgium	34.40	0.34	537.60	41.30	2556.27	370.16	3977.84	627.10	4637.01	753.16	4953.97	797.05	5157.80	821.97	5268.77	829.30	5398.11	833.52	5667.21	836.63	6467.45	843.18	7108.87	851.72	11597764	8.75
Denmark	116.30	0.00	323.87	7.07	1065.31	47.11	1479.60	72.82	1827.45	90.93	1971.87	97.14	2072.12	102.49	2187.04	104.22	2233.80	105.08	2318.69	105.77	2600.29	107.15	2853.42	107.50	5795502	8.81
France	44.04	0.93	446.50	25.97	1461.06	220.22	1907.82	349.69	2147.53	412.99	2229.12	436.54	2393.48	449.47	2495.31	455.66	2635.48	459.23	2795.92	462.50	3165.48	465.12	3883.60	467.77	65296963	8.86
Germany	32.75	0.07	524.15	3.19	1525.21	36.05	1882.08	71.29	2065.81	92.31	2162.64	101.38	2233.77	105.73	2319.04	107.67	2385.26	108.96	2466.27	109.79	2634.58	110.66	2851.10	111.56	83827321	9.20
UK	7.89	0.13	155.54	12.92	1123.82	180.71	2038.02	352.76	3019.69	472.95	3536.57	532.41	3906.24	577.36	4125.05	592.38	4274.81	601.16	4406.99	605.08	4618.52	608.29	4840.00	610.29	67943420	9.55
Sweden	76.27	0.10	296.36	13.26	1079.30	134.03	1865.89	253.13	2775.15	369.85	3523.17	438.21	4982.21	500.53	6450.65	536.53	7209.05	558.89	7504.02	568.68	7961.82	573.53	8291.71	575.31	10109375	10.07
Portugal	7.65	0.00	347.53	5.89	1627.29	49.45	2324.22	88.60	2738.77	114.11	3042.34	131.67	3549.91	147.67	4009.69	152.57	4563.66	162.88	4921.99	168.47	5223.11	173.08	5521.49	177.30	10191814	10.33
Czechia	10.92	0.00	189.32	0.84	561.32	12.88	693.23	20.54	769.50	26.42	846.98	29.59	929.87	30.71	1032.56	32.39	1231.77	32.86	1432.48	34.63	1780.68	36.50	2142.51	39.02	10712210	11.41
Estonia	20.35	0.00	405.52	0.75	986.67	18.84	1238.43	36.93	1316.07	45.98	1382.40	47.49	1484.91	47.49	1496.97	47.49	1518.08	47.49	1533.15	47.49	1638.68	47.49	1741.94	48.24	1326680	12.03
Turkey	0.01	0.00	42.96	0.89	674.17	14.18	1303.58	33.20	1674.60	46.09	1879.22	52.05	2074.01	56.56	2302.37	59.95	2521.14	63.48	2676.28	66.44	2892.80	69.73	3107.22	73.19	84482851	12.46
Slovakia	3.85	0.00	41.39	0.00	135.90	0.37	252.56	3.30	268.31	4.94	277.10	5.13	282.41	5.13	300.91	5.13	348.16	5.13	399.08	5.13	492.67	5.68	647.61	6.04	5460073	12.70
Italy	250.17	16.87	1333.08	136.33	2586.60	330.19	3269.98	441.89	3659.54	512.71	3814.12	546.69	3909.39	567.70	3970.11	576.73	4021.39	580.80	4071.91	583.34	4164.18	585.29	4343.26	586.59	60447245	12.87
Poland	0.819	0	27.77	0.37	167.941	5.496	297.86	13.845	431.373	21.429	571.544	26.607	745.139	32.103	875.085	37.308	991.397	41.43	1126.178	43.967	1399.359	48.115	1666.543	52.237	37850425	12.88015
Hungary	1.66	0.00	27.03	1.04	146.02	10.25	258.90	28.17	343.09	44.01	390.52	51.68	419.73	57.48	427.39	59.86	438.47	61.62	459.28	61.72	493.77	62.65	547.62	63.59	9656316	13.03
Lithuania	1.102	0	100.651	1.469	386.807	8.449	523.824	15.061	545.496	18.367	600.597	23.142	643.576	27.183	663.412	28.652	685.085	29.02	735.043	29.387	838.632	29.754	989.608	31.224	2725537	13.35834
Bulgaria	1.007	0.144	34.828	0.432	95.129	4.03	179.465	7.915	286.395	13.384	350.15	18.709	444.128	24.178	634.387	30.367	1032.605	37.706	1484.073	48.644	1974.83	67.785	2243.524	82.321	6953085	14.37964
Ukraine	0.00	0.00	2.584	0.091	57.416	1.669	185.783	4.596	357.801	9.329	485.78	14.245	664.704	19.527	914.808	24.398	1208.289	31.372	1461.777	36.356	1933.243	45.045	2517.163	53.003	43757273	15.95401
Average (for countries <10 % LTBI)	130.04	0.40	867.68	20.37	2124.48	136.19	2786.82	228.00	3146.65	279.55	3308.86	298.10	3430.93	309.58	3512.90	313.42	3602.97	315.70	3746.07	317.17	4146.34	319.16	4582.58	321.65		8.37
STDEV	192.73	0.55	938.59	26.17	1420.07	128.68	1509.03	196.92	1539.49	236.51	1572.01	251.32	1583.06	260.70	1588.63	263.46	1619.76	265.23	1713.63	266.23	2009.51	267.91	2311.44	270.34		0.88
Pop.																									323282729	
Average (for countries >10 % LTBI)	31.15	1.43	237.43	13.45	708.71	49.15	1032.81	78.93	1263.84	102.22	1430.33	115.43	1677.50	126.35	1923.19	132.62	2147.42	137.72	2317.11	141.19	2566.15	145.39	2813.35	149.01		12.62
STDEV	72.22	4.87	372.47	38.89	765.70	96.01	1002.28	133.70	1184.71	163.84	1317.75	180.57	1600.43	194.35	1916.26	201.58	2091.14	205.55	2148.41	206.93	2215.65	206.71	2261.31	205.97		1.61
Pop.																									283672884	

1. Note: Countries name in Black from ref 1.)

2. CpM: Cases per million; DpM: Deaths per million; Mar: March; Apr: April; Jun: June; Jul: July; Aug: August 2020

3. LTBI estimates from ref 8. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2017 (GBD 2017) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 2018.

[Available from http://ghdx.healthdata.org/gbd-results-tool; search term combination "Prevalence - Latent Tuberculosis Infection - Sex: Both - Age: All Ages (Percent)"]

4. STDEV: Standard deviation

Sup. Table 2

Table 2. COVID-19 Cases and Deaths of erstwhile East and West Germany states (Ref.1)

EAST GERMANY (Region)	COVID-19 Cases per 100k population							COVID-19 Deaths per million population					
States\Dates	10-Apr	8-May	5-Jun	3-Jul	31-Jul	28-Aug		10-Apr	8-May	5-Jun	3-Jul	31-Jul	28-Aug
Berlin: City State	133.5	173.4	193.5	232.2	256.6	308.3		NA	44.42	54.5	58.32	60.23	60.77
Brandenburg	84.74	122.6	129.2	136.2	142	154.2		19.03	51.95	61.86	65.82	66.22	66.22
Mecklenburg-Vorpommern [Mecklenburg-Western Pomerania]	38.31	45.46	48.13	50	55.09	62.93		6.84	11.81	12.44	12.44	12.44	12.44
Sachsen [Saxony]	94.33	121.2	130.8	134.1	136.4	147.2		15.72	45.19	52.06	55.01	55.26	55.26
Sachsen-Anhalt [Saxony-Anhalt]	54.9	75.09	78.55	86.11	92.17	102.1		8.201	21.87	25.06	26.88	28.25	29.16
Thüringen [Thuringia]	73.55	122.3	145	153.5	158.6	169.7		11.25	52.5	79.22	84.84	85.31	85.31
Average (without Berlin)	65.27	91.01	100.62	105.93	110.57	120.48		10.50	32.84	42.20	44.79	45.32	45.54
Average (with Berlin)	79.89	110.01	120.86	132.02	140.14	157.41		12.21	37.96	47.52	50.55	51.29	51.53

WEST GERMANY (Region)	COVID-19 Cases per 100k population							COVID-19 Deaths per million population					
Bremen: City State	72.52	164.1	225.6	246.9	262.8	292		19.08	46.98	64.59	77.8	80.74	82.21
Hamburg: City State	218.2	269	275.7	281.8	294.5	340.6		28.69	108.8	137	140.7	140.7	141.3
Baden-Württemberg	235.7	301.5	315.5	323.2	337.6	378.5		55.31	136.5	160.2	165.7	165.7	166.4
Bayern [Bavaria]	264.7	340.3	361.5	371.7	389.7	437.2		54.93	161.1	189	197.9	199.3	199.8
Hessen [Hesse]	101.8	143.4	162.6	174.6	193.7	246.9		17.81	64.09	76.65	80.95	81.74	82.7
Niedersachsen [Lower Saxony]	102.8	136.7	156.7	171	182.1	209.8		21.39	61.67	75.56	79.19	80.56	81.44
Nordrhein-Westfalen [North Rhine-Westphalia]	150.1	195.8	215.7	245.8	275.7	327.8		27.97	77.84	90.1	93.94	95.34	96.56
Rheinland-Pfalz [Rhineland-Palatinate]	121.1	154.3	165.6	173	184.9	219.7		14.66	46.9	56.18	57.4	58.14	58.38
Saarland	209.2	263.4	272.9	277.6	285.7	309.7		NA	141.9	168.2	176.3	176.3	176.3
Schleswig-Holstein	76.76	101	107	110	119.9	139.6		NA	42.01	50.28	52.35	53.03	53.72
Average (without Bremen & Hamburg)	157.77	204.55	219.69	230.86	246.16	283.65		32.01	91.50	108.27	112.97	113.76	114.41
Average (with Bremen & Hamburg)	155.29	206.95	225.88	237.56	252.66	290.18		29.98	88.78	106.78	112.22	113.16	113.88

Reference 1. https://www.citypopulation.de/en/germany/covid/ [Accessed on 10 October 2020].

Sup. Table 3

Table 3. i-CFR rates in East and West Germany region/ states					
EAST GERMANY (Region)	**i-CFR RATES AT INDICATED DATES**				
States\Date	**8-May**	**5-Jun**	**3-Jul**	**31-Jul**	**28-Aug**
Berlin: City State	2.562	2.817	2.512	2.347	1.971
Brandenburg	4.237	4.788	4.833	4.663	4.294
Mecklenburg-Vorpommern [Mecklenburg-Western Pomerania]	2.598	2.585	2.488	2.258	1.977
Sachsen [Saxony]	3.729	3.980	4.102	4.051	3.754
Sachsen-Anhalt [Saxony-Anhalt]	2.913	3.190	3.122	3.065	2.856
Thüringen [Thuringia]	4.293	5.463	5.527	5.379	5.027
Average (w/o Berlin)	3.609	4.194	4.229	4.098	3.780
Average (with Berlin)	3.450	3.932	3.829	3.659	3.274
WEST GERMANY					
Bremen: City State	2.863	2.863	3.151	3.072	2.815
Hamburg: City State	4.045	4.969	4.993	4.778	4.149
Baden-Württemberg	4.527	5.078	5.127	4.908	4.396
Bayern [Bavaria]	4.734	5.228	5.324	5.114	4.570
Hessen [Hesse]	4.469	4.714	4.636	4.220	3.350
Niedersachsen [Lower Saxony]	4.511	4.822	4.631	4.424	3.882
Nordrhein-Westfalen [North Rhine-Westphalia]	3.975	4.177	3.822	3.458	2.946
Rheinland-Pfalz [Rhineland-Palatinate]	3.040	3.393	3.318	3.144	2.657
Saarland	5.387	6.163	6.351	6.171	5.693
Schleswig-Holstein	4.159	4.699	4.759	4.423	3.848
Average (w/o Bremen & Hamburg)	4.473	4.928	4.893	4.621	4.034
Average (w/ Bremen & Hamburg)	4.290	4.727	4.724	4.479	3.924

Note: East Germany states (est. 22.5% LTBI of vulnerable population (Ref..2) consistently reported lower i-CFR as compared to West Germany States (est. 9.2% LTBI of vulnerable population). E. Germany with higher trained immunity correlate consistently had 20-30% lower CFR as compared to W. Germany states. The inclusion of Berlin in East Germany region, and that of Hamburg and Bermen in West Germany region decreased the closing trend of the i-CFR with passage of time (Compare covariation of Red and Green trend lines with Orange and Light green in Fig. 2C) that could be reflective of more LTBI positives in Berlin as compared to Hamburg and Bremen.

Reference 2. Singh S, Maurya RP, Singh RK. 'Trained immunity' from *Mycobacterium spp.* exposure or BCG vaccination and COVID-19 outcomes. *medRxiv.* DOI::10.1101/2020.07.11.20151308.